A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2001
10/18/2001	WO2001077057A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001077055A2 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001076644A2 Lipid-based systems for targeting diagnostic agents
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076622A2 Immunogenic peptides derived from prostate-specific antigen (psa) and uses thereof
10/18/2001	WO2001076621A2 Methods and compositions for treating neoplasms
10/18/2001	WO2001076616A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	WO2001076615A2 Cxcr4 agonist treatment of hematopoietic cells
10/18/2001	WO2001076606A2 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
10/18/2001	WO2001076597A2 A method of administering an antitumour compound using a polymer-camptothecin conjugate
10/18/2001	WO2001076595A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
10/18/2001	WO2001076586A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	WO2001076575A2 The treatment of respiratory diseases
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076569A2 An improved pt(iv) antitumor agent
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076567A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	WO2001076556A2 Lipid-based drug delivery systems against parasitic infections
10/18/2001	WO2001076555A2 Lipid-based drug delivery systems for topical application
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001076451A2 Diagnosis of diseases associated with metabolism
10/18/2001	WO2001045737A3 Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
10/18/2001	WO2001039724A3 Phosphonate compounds
10/18/2001	WO2001038548A3 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
10/18/2001	WO2001038352A3 Methods of inhibiting metastasis
10/18/2001	WO2001036626A3 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
10/18/2001	WO2001031015A3 36p6d5: secreted tumor antigen
10/18/2001	WO2001026683A3 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses
10/18/2001	WO2001025213B1 Pyrrolo imidazole derivatives and their use as medicaments
10/18/2001	WO2001023540A3 P-glycoproteins and uses thereof
10/18/2001	WO2001020004A3 Protein phosphatase and kinase proteins
10/18/2001	WO2000044893A9 In vitro activated gamma delta lymphocytes
10/18/2001	WO2000044782A9 Ewing's tumour antigen, nucleic acid and antibodies
10/18/2001	WO2000043498A9 Human liver progenitors
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	WO2000020041A9 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
10/18/2001	US20010032014 Stent coating
10/18/2001	US20010031882 Lipoxin compounds and their use in treating cell proliferative disorders
10/18/2001	US20010031788 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects
10/18/2001	US20010031782 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
10/18/2001	US20010031773 Administering (5-aryl-1,2,4-thiadiazol)-3-yl thiourea and urea derivatives to treat hepatitis, HIV and Kaposi sarcoma, as viricides and anticarcinogenic agents
10/18/2001	US20010031770 Pyridoxal analogues and methods of treatment
10/18/2001	US20010031766 Prostaglandin receptor ligands
10/18/2001	US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide
10/18/2001	US20010031740 Mixture containing organic halide
10/18/2001	US20010031722 Methods and reagents for facilitating transcription
10/18/2001	US20010031485 Nucleic acid coding for fusion protein which binds receptor; internalized by endocytosis; inhibits ribosomes and angiogenesis; therapy for tumors, metastasis, eye disorders, chronic inflammation and ischemic injuries
10/18/2001	US20010031282 Dissolving solid in dimethyl ether under pressure; precipitation; separation
10/18/2001	US20010031265 Soaking in solution; then culturing
10/18/2001	US20010031261 Use of genetically engineered antibodies to treat multiple myeloma
10/18/2001	US20010031252 Endogenous immune response
10/18/2001	DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma
10/18/2001	DE10016877A1 (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung (Glyco) proteins with high immunoreactivity, and a method for their preparation
10/18/2001	DE10016559A1 System für den Transport von Aktivstoffen in einem biologischen System System for transporting active substances in a biological system
10/18/2001	DE10013782A1 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln 4-fluoroalkyl-2H-benzopyrans with antiestrogenic action, processes for their preparation, pharmaceutical compositions containing them and their use for the preparation of medicaments
10/18/2001	DE10013539A1 Lipopolysaccharide aus Escherichia coli Lipopolysaccharides from Escherichia coli
10/18/2001	CA2406485A1 Hpv-specific short-mers
10/18/2001	CA2406484A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2406188A1 Methods for ansamitocin production
10/18/2001	CA2406128A1 Methods and compositions for treating neoplasms
10/18/2001	CA2406033A1 Anti-d monoclonal antibodies
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405907A1 Cxcr4 agonist treatment of hematopoietic cells
10/18/2001	CA2405800A1 Novel secreted protein
10/18/2001	CA2405779A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	CA2405730A1 Serine-threonine kinase
10/18/2001	CA2405554A1 Intracorporeal medicaments comprising halogenated xanthenes for high energy phototherapeutic treatment of disease
10/18/2001	CA2405476A1 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	CA2405124A1 Gene coding for erbin, and diagnostic and therapeutic uses thereof
10/18/2001	CA2405104A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405083A1 New bromodomain protein
10/18/2001	CA2405070A1 Estrogen agonist/antagonist metabolites
10/18/2001	CA2404971A1 Human protein kinases and protein kinase-like enzymes
10/18/2001	CA2404760A1 Oxazole derivatives and their uses as tyrosine kinase inhibitors
10/18/2001	CA2404630A1 Cathepsin cysteine protease inhibitors
10/18/2001	CA2404265A1 Human ovarian mesothelial cells and methods of isolation and uses thereof
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2404087A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	CA2403425A1 Multivalent antibodies and uses therefor
10/18/2001	CA2403365A1 Quinazoline compounds
10/18/2001	CA2403263A1 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2403144A1 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2401290A1 Novel g protein-coupled receptor protein and dna thereof
10/18/2001	CA2372352A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/17/2001	EP1146125A1 Poxvirus with targeted infection specificity
10/17/2001	EP1146050A1 Remedies
10/17/2001	EP1146046A2 Pyropheophorbides and their use in photodynamic therapy
10/17/2001	EP1146043A1 Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them
10/17/2001	EP1145718A1 DICARBA-closo-DODECABORANE DERIVATIVES
10/17/2001	EP1145713A1 Telomerase inhibitors
10/17/2001	EP1145011A2 Compositions and methods for the diagnosis and treatment of tumor
10/17/2001	EP1145001A2 (in vitro) model for gastrointestinal inflammation
10/17/2001	EP1144997A2 Methods and compounds for modulating nuclear receptor activity
10/17/2001	EP1144690A1 Antisense modulation of cellular inhibitor of apoptosis-2 expression
10/17/2001	EP1144682A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/17/2001	EP1144650A2 Goodpasture antigen binding protein

1 ... 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 ... 2211